In this series, we review ISO 14971 (Application of risk management to medical devices)—its history, the principles embedded within it and how it relates to other standards and regulation
The value in having standards drawn up by experts is that they should be able to withstand the test of time as well as pressure from outside influences. Such is the case with ISO 14971, created in 1998 by a joint International Organisation for Standardisation (ISO)/International Electrotechnical Commission (IEC) Working Group (JWG1).
In 2012 the European Commission (EC) raised legal objections to several harmonised standards. In particular, the Commission determined that compliance with ISO 14971 could not guarantee conformity with the Essential Requirements relating to risk as contained in the European Medical Devices Directive (MDD). In response, JWG1 pointed out that the differences between the standard and the Essential Requirements were due to imprecise wording in the Directive, rather than to inadequacies in ISO 14971. The Commission’s position was that the wording of the MDD was the only thing that mattered. The two bodies were at an impasse until the MDD was replaced by the Medical Device Regulation (MDR), which, through lobbying, national standards bodies ensured reflected the principles set out in ISO 14971.
The drive to develop a common understanding of risk
Further controversy around managing risk in the medical device sector arose in 2021 when the ISO and IEC technical management boards aimed to adopt a common understanding of risk management principles and use the same definitions across all industry sectors.
The risk model they chose was that of ISO 3100:2018, as it provides guidelines on a common approach to managing risks faced by organisations and defines risk as “the effect of uncertainty on objectives.” This concept relates risk not only to potential harm but also accepts that it can have positive consequences. Proponents of adopting the ISO 3100 model held that it could be applied universally since it is based on the valid concept, embedded in ISO 14971 as well, that risk is all about investigating the role of uncertainty in predicting outcomes. Users of ISO 14971 would do well to remember this.
ISO 3100 also impacts the medical devices sector through ISO 9001, which is universally applicable and underpins the requirements of ISO 13485 for medical device quality management systems. ISO 9001 requires that quality assurance be centred on systematic, proactive, risk-based thinking. It relates the concept of risk to the uncertainty of achieving an expected result and refers to opportunity as the possibility of exceeding expectations and going beyond stated objectives. These principles are viewed as sound by industry experts.
A Joint ISO/IEC Task Force was set up in 2021 with the goal of recommending a common understanding of risk across all sectors in three years. In the process, it soon became apparent that the model chosen for universal application was incompatible with the concept of risk as applied to healthcare. In healthcare, risk terminology is enshrined in healthcare regulation and is, therefore, not negotiable.
The way the healthcare sector deals with risk is clearly defined in ISO/IEC Guide 51, on which ISO 14971 was based. It is consistent with principles applicable across all sectors that focus on avoiding harm to people or damage to property. These principles have been implemented effectively for over 30 years and have been adopted by the International Medical Device Regulators Forum (IMDRF) and many national and regional regulations, including the MDR. It took much less than three years for the ISO and IEC technical management boards’ proposal to be abandoned.
Essentially, we conclude that the model we use in the healthcare sector is fit for purpose and consequently, cast in stone.
In this section
-
Digital Disruption
-
Clinical strategies to optimise SaMD for treating mental health
-
Digital Disruption: Surveying the industry's evolving landscape
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- mHealth wearables
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Decoding AI in software as a medical device (SaMD)
-
Software as a medical device (SaMD)
-
Clinical strategies to optimise SaMD for treating mental health
-
Patient Centricity
-
Accelerating clinical development through DHTs
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Representation and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Prioritising patient-centred research for regulatory approval
-
Accelerating clinical development through DHTs
-
Regulatory Intelligence
-
Accelerating access
-
Meeting requirements for Joint Clinical Assessments
-
Navigating the regulatory landscape in the US and Japan:
-
Preparing for ICH GCP E6(R3) implementation
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
Exploring FDA guidance for modern Data Monitoring Committees
-
Streamlining dossier preparation
-
Accelerating access
-
Therapeutics insights
-
Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
-
Central Nervous System
-
A mind for digital therapeutics
-
Challenges and opportunities in traumatic brain injury clinical trials
-
Challenges and opportunities in Parkinson’s Disease clinical trials
-
Early, precise and efficient; the methods and technologies advancing Alzheimer’s and Parkinson’s R&D
-
Key Considerations in Chronic Pain Clinical Trials
-
ICON survey report: CNS therapeutic development
-
A mind for digital therapeutics
-
Glycomics
- Infectious Diseases
- NASH
- Obesity
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Endocrine and Metabolic Disorders
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Demystifying the Systematic Literature Reviews
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
More than monitoring
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
-
Blended solutions insights
-
Clinical trials in Japan: An enterprise growth and management strategy
-
How investments in supply of CRAs is better than competing with the demand for CRAs
-
The evolution of FSP: not just for large pharma
-
Embracing a blended operating model
-
Observations in outsourcing: Survey results show a blended future
-
Clinical trials in Japan: An enterprise growth and management strategy
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Behind Biotech: Stories of science and resilience
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Integrating openness and precision for competitive advantage
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel